What is the difference between Ji Sandai/Bingtongsha and Ji Erdai?

Epclusa and Harvoni are both oral direct-acting antiviral drugs (DAAs) for the treatment of hepatitis C (HCV). Although the two have similar treatment concepts, they have key differences in drug structure, applicable population and scope of use. Understanding the difference between the two is of great significance for patients to scientifically choose treatment options and improve the chance of cure.

First of all, from the perspective of drug ingredients, the second generation of Genisitin is composed of Sofosbuvir and Ledipasvir, while the third generation of Genisitin is a compound of sofosbuvir and Velpatasvir. Although both use sofosbuvir as the core ingredient, the difference in accompanying ingredients directly determines the difference in antiviral spectrum. Ji Erdai is mainly used to treat HCV genotype 1 and 4 infections, and its indications are relatively limited. As a full-genotype treatment drug, Jisandai is suitable for almost all genotype (type 1-6) infections, especially for genotype 3 and other types that are more difficult to treat with traditional methods, showing higher broad adaptability.

Secondly, in terms of applicable groups, Jisandai is more flexible. Regardless of whether there is a background of liver cirrhosis, whether combined with HIV, or even in patients with impaired renal function to a certain extent, Jisandai has shown good tolerability and efficacy. The second generation of Jilin is more used in patients with genotype 1 infection who have not received treatment in the past or who do not have cirrhosis. Its efficacy is limited in some complex cases.

Furthermore, from the perspective of clinical application, Jisandai often can start treatment without genotyping, simplifying the diagnosis process and waiting time. In contrast, detailed viral typing and drug resistance assessment are usually required before using second-generation drugs to determine its suitability for treatment. In addition, Gisanda can also be used in combination with ribavirin in some cases to enhance the therapeutic effect, especially for patients with poor liver function or previous treatment failure.

Reference: https://www.epclusa.com/